Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Peripheral T-Cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Welcome to The Peripheral T-Cell Lymphoma (PTCL) Channel

VJHemOnc presents The Peripheral T-Cell Lymphoma (PTCL) Channel – a source of video interviews, podcasts and roundtable discussions with top experts on the most exciting and impactful updates in the field of PTCL from major international congresses.

The Peripheral T-Cell Lymphoma Channel covers all key research areas including updates on antibody-drug conjugates, ALK inhibitors, and the use of checkpoint inhibitors.

Is the biology of T-cell malignancies too complex for a single-agent immunotherapy approach? 0:51
Is the biology of T-cell malignancies too complex for a single-agent immunotherapy approach?
Yumeng Zhang • 8 Dec 2025
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas 1:57
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam • 8 Dec 2025
Key unmet needs in PTCL & the need for more research in this space 2:51
Key unmet needs in PTCL & the need for more research in this space
Tetiana Skrypets • 20 Jun 2025
The International Prospective T-Cell Project 2.0: radiomics and total metabolic tumor volume 3:19
The International Prospective T-Cell Project 2.0: radiomics and total metabolic tumor volume
Tetiana Skrypets • 20 Jun 2025
Key challenges in the treatment of patients with PTCL 1:18
Key challenges in the treatment of patients with PTCL
Gandhi Damaj • 31 Mar 2025
The EBMT consensus guidelines for alloSCT in T-cell lymphoma 5:03
The EBMT consensus guidelines for alloSCT in T-cell lymphoma
Gandhi Damaj • 31 Mar 2025
Combining JAK inhibition and immune checkpoint blockade for the treatment of 9p amplified lymphomas 3:28
Combining JAK inhibition and immune checkpoint blockade for the treatment of 9p amplified lymphomas
Jennifer Amengual • 6 Dec 2024
Predicting response and survival in patients with PTCL treated with pembrolizumab and romidepsin 1:46
Predicting response and survival in patients with PTCL treated with pembrolizumab and romidepsin
Swaminathan Iyer • 9 Dec 2024
Long-term follow-up of a Phase II study combining azacitidine with CHOP in previously untreated PTCL 3:48
Long-term follow-up of a Phase II study combining azacitidine with CHOP in previously untreated PTCL
Jia Ruan • 9 Dec 2024
Updates in T-cell leukemia/lymphoma
Francine Foss et al. • 9 Oct 2024
Optimizing frontline treatment for PTCL: introducing novel agents into CHOP-based regimens 3:25
Optimizing frontline treatment for PTCL: introducing novel agents into CHOP-based regimens
Neha Mehta-Shah • 30 Aug 2024
Unmet needs in PTCL: improving frontline therapy and personalizing treatment 2:30
Unmet needs in PTCL: improving frontline therapy and personalizing treatment
Neha Mehta-Shah • 30 Aug 2024
Therapeutic approaches in the front-line for patients with PTCL 1:54
Therapeutic approaches in the front-line for patients with PTCL
Neha Mehta-Shah • 30 Aug 2024
Findings from the Ro-CHOP trial in patients with R/R PTCL 1:23
Findings from the Ro-CHOP trial in patients with R/R PTCL
Vincent Camus • 14 Jun 2024
PET imaging to predict treatment outcomes: follow-up from the ECHELON-2 trial 3:17
PET imaging to predict treatment outcomes: follow-up from the ECHELON-2 trial
Swaminathan Iyer • 11 Dec 2023
The significance of CD30 in the response to brentuximab vedotin for patients with T-cell lymphoma 2:39
The significance of CD30 in the response to brentuximab vedotin for patients with T-cell lymphoma
Swaminathan Iyer • 11 Dec 2023

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

Diamond Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals